Milanova Tsveta's most recent trade in Agios Pharmaceuticals Inc was a trade of 6,000 Performance share units done . Disclosure was reported to the exchange on June 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 6,000 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 28,892 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 2,770 | 26,122 (0%) | 0% | 33.5 | 92,906 | Common stock |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 24,573 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 22,892 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 8,476 | 21,710 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 8,476 | 8,475 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 32.18 per share. | 03 Jan 2025 | 2,804 | 18,906 (0%) | 0% | 32.2 | 90,233 | Common stock |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 60,000 | 60,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,000 | 17,000 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,448 | 0 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,448 | 14,852 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Milanova Tsveta | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 1,618 | 13,234 (0%) | 0% | 21.6 | 35,014 | Common stock |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 8,475 | 12,306 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Milanova Tsveta | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 8,475 | 16,951 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.32 per share. | 03 Jan 2024 | 2,902 | 9,404 (0%) | 0% | 22.3 | 64,773 | Common stock |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,449 | 5,448 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,449 | 5,449 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 1,618 | 3,831 (0%) | 0% | 28.4 | 45,886 | Common stock |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 135,682 | 135,682 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 25,426 | 25,426 | - | - | Restricted stock units |